Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy
Open Access
- 1 January 2011
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2011 (1) , 718710
Abstract
Newcastle disease virus (NDV) is an avian virus that causes deadly infection to over 250 species of birds, including domestic and wild‐type, thus resulting in substantial losses to the poultry industry worldwide. Many reports have demonstrated the oncolytic effect of NDV towards human tumor cells. The interesting aspect of NDV is its ability to selectively replicate in cancer cells. Some of the studies have undergone human clinical trials, and favorable results were obtained. Therefore, NDV strains can be the potential therapeutic agent in cancer therapy. However, investigation on the therapeutic perspectives of NDV, especially human immunological effects, is still ongoing. This paper provides an overview of the current studies on the cytotoxic and anticancer effect of NDV via direct oncolysis effects or immune stimulation. Safety of NDV strains applied for cancer immunotherapy is also discussed in this paper.Keywords
Funding Information
- Ministry of Science, Technology and Innovation
- Universiti Putra Malaysia
This publication has 90 references indexed in Scilit:
- Selective Cytotoxicity of Goniothalamin against Hepatoblastoma HepG2 CellsMolecules, 2011
- Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-NeuraminidaseJournal of Virology, 2009
- Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune ResponsesMolecular Therapy, 2009
- Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogensProceedings of the National Academy of Sciences, 2007
- p53-Independent Endoplasmic Reticulum Stress-Mediated Cytotoxicity of a Newcastle Disease Virus Strain in Tumor Cell LinesJournal of Virology, 2007
- Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell LinesJournal of Virology, 2006
- Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancerCancer Immunology, Immunotherapy, 1992
- FEC (5-Fluorouracil-Epirubicin-Cyclophosphamide) Monthly Versus FEC Weekly in Metastatic Breast Cancer: First results of a randomized trialActa Oncologica, 1992
- In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1991
- Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccineCancer Immunology, Immunotherapy, 1990